Genentech Licenses A Cancer Metabolism Program From Forma, With Option To Buy
This article was originally published in The Pink Sheet Daily
Executive Summary
The Roche-owned biotech licensed a novel oncology target from the startup, but could take outright possession of the program - with a payout for VCs.